ArticleFrontiers in medicine2025
Leveraging public health infrastructures to support sexual health for women living in the Southern United States.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acceptability and Feasibility of Home-Based Human Papillomavirus Self-Testing as Primary Screening for Cervical Cancer Detection in the State of Alabama.Journal of community health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: Camellia is a single-arm longitudinal cohort study. We engaged a Community Advisory Board to support refinement of an existing mHealth app platform for use among cis- and transwomen in Alabama, one of seven states prioritized in the federal Ending the HIV Epidemic (EHE) strategy. We partnered with the Alabama Department of Public Health to recruit from a database of women recently diagnosed with gonorrhea or syphilis, aged 18-50, across Alabama. Potential participants are recruited by telephone. A home-based HIV and sexually transmitted infection (STI) testing program allows the study to offer tailored sexual health information, testing, linkage to care and support while assessing STI and HIV incidence and associated predictors. Methods: Study participants are enrolled into the digital Camellia Cohort in which they complete home-based HIV and STI testing and online surveys every 6 months. Participants are followed for at least 24 months or until study completion (up to 42 months). Primary outcomes include predictors, mediators and moderators for HIV and STI incidence and pre-exposure prophylaxis (PrEP) use via self-report, medical record review, and dried blood spots. Conclusion: The Camellia Cohort integrates epidemiologic methods, mHealth technology, and data science to better characterize HIV transmission dynamics and engagement in the prevention care cascade among women in an EHE focus state. This study will provide critical insights into the feasibility and acceptability of a remote, light-touch cohort design, while also providing data on STI and HIV incidence, PrEP use, and key mediators and moderators influencing prevention behaviors among women with indications for PrEP in this high-priority region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.